1. Home
  2. MTA vs ASMB Comparison

MTA vs ASMB Comparison

Compare MTA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$9.08

Market Cap

636.3M

Sector

N/A

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$27.09

Market Cap

512.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
ASMB
Founded
1983
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
636.3M
512.1M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
MTA
ASMB
Price
$9.08
$27.09
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$9.00
$44.20
AVG Volume (30 Days)
405.9K
130.1K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$81.63
N/A
Revenue Next Year
$62.44
$638.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$20.23
52 Week High
$9.30
$39.71

Technical Indicators

Market Signals
Indicator
MTA
ASMB
Relative Strength Index (RSI) 70.69 55.77
Support Level $6.33 $26.29
Resistance Level $9.25 $30.36
Average True Range (ATR) 0.33 1.03
MACD 0.17 0.16
Stochastic Oscillator 89.24 90.81

Price Performance

Historical Comparison
MTA
ASMB

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Share on Social Networks: